Guide · Updated April 2026
GLP-1 and Gallbladder Problems: What to Watch For
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) increase gallstone risk by roughly 1.5 to 2.5 times compared to placebo. In the SURMOUNT-1 trial, cholelithiasis (gallstones) occurred in about 0.6% of tirzepatide users versus 0% on placebo. The STEP 1 trial reported gallbladder disorders in 1.5% of semaglutide users versus 0.5% on placebo. Faster weight loss drives most of this risk, not the drugs themselves.
Why GLP-1 Gallbladder Gallstones Happen During Rapid Weight Loss
The connection between GLP-1 medications and gallbladder problems is not unique to these drugs. It is a well-documented consequence of rapid weight loss from any cause: bariatric surgery, very low calorie diets, or medications like semaglutide and tirzepatide.
Here is what happens. Your liver processes cholesterol and excretes it into bile, which is stored in the gallbladder. When you lose weight quickly, your liver dumps extra cholesterol into bile faster than your gallbladder can handle. The bile becomes supersaturated with cholesterol, and those crystals clump together into gallstones.
GLP-1 receptor agonists add a second factor. These medications slow gastric emptying and reduce overall food intake. When you eat less, your gallbladder contracts less often. Bile sits stagnant for longer periods. Stagnant bile plus excess cholesterol creates ideal conditions for stone formation.
I have been on Mounjaro for months, and my appetite dropped dramatically in the first 8 weeks. I was eating maybe 1,200 calories some days, which is exactly the kind of rapid caloric restriction that increases gallstone risk. It is one of those side effects that does not get enough attention compared to nausea or fatigue.
What the Clinical Trials Show
The major GLP-1 weight loss trials all tracked gallbladder events. The numbers are small in percentage terms but real.
SURMOUNT-1 (Tirzepatide)
The SURMOUNT-1 trial (NEJM, July 2022) enrolled 2,539 adults with obesity and no diabetes. Participants lost 16.0% to 22.5% of body weight over 72 weeks depending on dose. Gallbladder-related adverse events were uncommon but dose-dependent:
- Cholelithiasis (gallstones): 0.6% at 15mg vs 0% placebo
- Cholecystitis (gallbladder inflammation): reported in a small number of participants
- Most gallbladder events occurred after week 24, coinciding with the steepest weight loss phase
STEP 1 (Semaglutide)
The STEP 1 trial (NEJM, February 2021) enrolled 1,961 adults using semaglutide 2.4mg. Mean weight loss was 14.9% over 68 weeks. Gallbladder disorders occurred in 1.5% of semaglutide users versus 0.5% on placebo. That is a threefold increase in relative terms, though the absolute numbers stayed low.
Pooled Analysis Across Trials
A 2023 meta-analysis published in Diabetes, Obesity and Metabolism looked across multiple GLP-1 trials and found:
- GLP-1 receptor agonists increased gallbladder event risk by approximately 1.5 to 2.5 times
- The risk was highest in patients who lost more than 15% of body weight
- Semaglutide showed slightly higher gallbladder event rates than tirzepatide, likely because of differences in trial design and patient populations
| Trial | Drug | Weight Loss | Gallbladder Event Rate | Placebo Rate |
|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15mg | 22.5% | ~0.6% | 0% |
| STEP 1 | Semaglutide 2.4mg | 14.9% | 1.5% | 0.5% |
| SURMOUNT-5 | Tirzepatide (max) | 20.2% | Reported | Reported |
| STEP 5 | Semaglutide 2.4mg | 15.2% (2yr) | 2.6% | 1.2% |
The pattern is consistent: more weight loss equals more gallstone risk. This is not specific to GLP-1s. Bariatric surgery patients face gallstone rates of 30-40% in the first year post-surgery when losing 25%+ of body weight.
Risk Factors: Who Is Most Vulnerable
Not everyone on a GLP-1 faces the same gallbladder risk. Certain groups should pay closer attention.
Higher risk:
- Women (2-3x higher gallstone prevalence than men at baseline)
- Age over 40
- Rapid weight loss of more than 1.5 lbs per week sustained over months
- History of gallstones or gallbladder sludge
- Family history of gallbladder disease
- Higher starting BMI (more cholesterol mobilization during weight loss)
- Very low fat diets (the gallbladder needs dietary fat to contract and empty)
Lower risk:
- Slower, steady weight loss
- Adequate dietary fat intake (at least 7-10g per meal)
- Younger patients
- Those with no personal or family history of gallstones
If you fall into multiple higher-risk categories, this is worth discussing with your prescribing provider before you start a GLP-1. It does not mean you should avoid the medication. It means you should know what to watch for.
Compare GLP-1 providers
Browse Provider Directory →Symptoms You Should Not Ignore
Gallstones can sit in your gallbladder for years without causing any problems. These are called “silent” gallstones and they are common in the general population. The issue is when a stone blocks a bile duct or causes inflammation.
Warning signs of a gallbladder attack:
- Sudden, intense pain in the upper right abdomen (just below the ribs)
- Pain that radiates to the right shoulder blade or between the shoulder blades
- Nausea and vomiting that feels different from your usual GLP-1 nausea
- Pain that worsens after eating, especially fatty meals
- Episodes lasting 30 minutes to several hours
- Fever or chills (this suggests infection and needs emergency care)
Here is the tricky part for GLP-1 users: nausea and stomach pain overlap with normal medication side effects. The key difference is location and intensity. GLP-1 nausea is usually a general queasiness that comes and goes. Gallbladder pain is sharp, localized to the upper right, and often hits after meals. If you are experiencing upper right abdominal pain that is new or different from your typical GLP-1 symptoms, get it checked. An abdominal ultrasound can diagnose gallstones quickly and cheaply.
Prevention Strategies That Actually Work
You cannot eliminate gallstone risk during rapid weight loss, but you can reduce it meaningfully.
1. Do Not Skip Dietary Fat Entirely
This is counterintuitive for people trying to lose weight, but your gallbladder needs fat to function. Every time you eat fat, your gallbladder contracts and empties bile. If you go very low-fat (which many GLP-1 users do because fatty food makes them feel sick), bile sits and stagnates.
Aim for at least 7-10 grams of fat per meal. That is about a tablespoon of olive oil, a handful of almonds, or half an avocado. This is where tracking your daily food intake on Mounjaro becomes practical, not just for calories but for making sure you are getting enough fat to keep your gallbladder working.
2. Maintain Adequate Protein Intake
There is some evidence that adequate protein helps with bile composition. Protein also helps with muscle preservation during GLP-1 weight loss, so this is a two-for-one benefit. Aim for at least 0.7g per pound of body weight. Our protein guide breaks this down further.
3. Avoid “Crash Dieting” on Top of the Medication
GLP-1s already reduce your appetite significantly. Layering extreme caloric restriction on top of that can push weight loss into the danger zone for gallstones (more than 3 lbs per week consistently). Let the medication do its job. Eat when you are hungry, even if it is less than before.
4. Stay Hydrated
Dehydration concentrates bile. This is basic but easy to forget when your appetite is suppressed and you are not thinking about food or drinks as often. Two to three liters of water daily is a reasonable target for most adults on GLP-1 therapy.
5. Consider Ursodiol for High-Risk Patients
Ursodiol (ursodeoxycholic acid) is a prescription medication that dissolves cholesterol-based gallstones and prevents new ones from forming. It is commonly prescribed to bariatric surgery patients during rapid weight loss. Some GLP-1 prescribers are starting to offer it prophylactically for patients losing weight quickly, though this is not yet standard practice.
If you have a history of gallstones or multiple risk factors, ask your doctor about ursodiol. The typical preventive dose is 300mg twice daily.
| Prevention Strategy | Effectiveness | Cost | Notes |
|---|---|---|---|
| Include fat in every meal (7-10g) | Moderate | Free | Keeps gallbladder contracting regularly |
| Adequate protein (0.7g/lb) | Moderate | Varies | Also helps with muscle preservation |
| Hydration (2-3L/day) | Low-moderate | Free | Prevents bile concentration |
| Avoid extreme caloric restriction | Moderate | Free | Let the medication control appetite |
| Ursodiol prophylaxis | High | $30-60/mo | Prescription required, not standard practice yet |
What Happens If You Do Get Gallstones
If you develop symptomatic gallstones on a GLP-1, the treatment pathway is the same as for anyone else with gallstone disease.
Watchful waiting: If your gallstones are discovered incidentally (during an imaging scan for another reason) and you have no symptoms, your doctor may recommend monitoring. About 80% of gallstones never cause symptoms.
Cholecystectomy (gallbladder removal): This is the definitive treatment for symptomatic gallstones. It is one of the most common surgeries in the US (over 700,000 per year). Most are done laparoscopically with a 1-2 day recovery. You do not need a gallbladder to live normally. Your liver continues producing bile, which drains directly into the small intestine.
Medication (ursodiol): For patients who cannot have surgery, ursodiol can slowly dissolve cholesterol stones over 6-24 months. Success rates are moderate and stones often recur after stopping the medication.
Do you need to stop your GLP-1? Not necessarily. This depends on the severity and your doctor’s judgment. Many patients continue GLP-1 therapy after gallbladder removal with no issues. If you are having recurrent gallbladder attacks, your doctor may pause the medication until the situation is resolved. The decision to continue or stop should be based on a risk-benefit conversation, not a blanket rule.
The Bigger Picture: Risk vs Benefit
Gallstone risk needs to be weighed against what these medications actually accomplish. In SURMOUNT-1, tirzepatide at 15mg produced 22.5% body weight loss (52 lbs on average) over 72 weeks. In SURMOUNT-5 (NEJM, May 2025), tirzepatide outperformed semaglutide with 20.2% weight loss versus 13.7%.
The health benefits of that magnitude of weight loss are substantial: reduced cardiovascular risk, improved blood pressure, better blood sugar control, less joint pain, improved sleep apnea. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in adults with obesity.
A 1-2% absolute risk of gallbladder events is real but small compared to these benefits. For most people, the math favors treatment, especially when you know what to watch for and take preventive steps.
If you are weighing the cost of GLP-1 treatment against these risks, the gallbladder concern should not be a dealbreaker. It should be something you monitor, not something that stops you from starting.
The Bottom Line
GLP-1 medications modestly increase gallstone risk, primarily because of rapid weight loss rather than a direct drug effect. The absolute risk is low (1-2.5% in clinical trials), and most gallbladder events are manageable. Keep dietary fat in your meals, avoid extreme caloric restriction on top of the medication, stay hydrated, and know the warning signs. If you have a history of gallstones or multiple risk factors, ask about ursodiol. Do not let gallbladder fear keep you from a medication class that produces 15-22% weight loss and real cardiovascular protection.
Check your coverage options in our provider directory or use the body composition calculator to track your progress while staying alert to changes.
FAQ
Can GLP-1 medications cause gallstones?
Yes. GLP-1 receptor agonists increase gallstone risk by 1.5 to 2.5 times compared to placebo in clinical trials. This is primarily driven by rapid weight loss, which causes the liver to excrete excess cholesterol into bile. The absolute risk remains low at 1-2.5% in major trials like SURMOUNT-1 and STEP 1.
How do I tell the difference between GLP-1 nausea and a gallbladder attack?
GLP-1 nausea is usually a diffuse, general queasiness that comes and goes throughout the day. A gallbladder attack causes sharp, sudden pain specifically in the upper right abdomen, often radiating to the shoulder blade, and typically worsens after fatty meals. Gallbladder episodes last 30 minutes to several hours. If your pain is localized and intense, see your doctor for an ultrasound.
Should I stop my GLP-1 if I get gallstones?
Not automatically. Many people continue GLP-1 therapy even after a gallbladder diagnosis or removal. The decision depends on symptom severity and should be made with your prescriber. If gallbladder attacks are recurring, your doctor may pause the medication until the issue is resolved, often through a straightforward laparoscopic cholecystectomy.
Does the type of GLP-1 matter for gallbladder risk?
Both semaglutide and tirzepatide carry gallbladder risk. STEP 1 showed 1.5% gallbladder events for semaglutide versus 0.5% placebo. SURMOUNT-1 showed about 0.6% for tirzepatide versus 0% placebo. The differences likely reflect trial design and weight loss magnitude rather than one drug being inherently safer for the gallbladder.
Can I prevent gallstones while on a GLP-1?
You can reduce the risk significantly. Include 7-10g of fat per meal to keep the gallbladder contracting. Maintain adequate protein and hydration. Avoid stacking extreme caloric restriction on top of the medication. For high-risk patients (prior gallstones, female, over 40), ursodiol at 300mg twice daily is an effective preventive option used routinely in bariatric surgery patients.
Related
Guides:
- Side Effects Guide · Constipation Guide · Nausea on Mounjaro
- Muscle Preservation Protocol · Body Composition Guide · Protein on GLP-1
- Fat Loss vs Weight Loss · DEXA Scan Results · What I Eat on Mounjaro
- GLP-1 Cost Guide · Cheapest GLP-1 Online · Side Effects Month by Month
Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate
Compare: All Providers · Best GLP-1 Programs · All Guides